应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01801 信达生物
休市中 04-26 16:08:20
39.150
+0.600
+1.56%
最高
39.950
最低
38.500
成交量
728.66万
今开
39.150
昨收
38.550
日振幅
3.76%
总市值
635.28亿
流通市值
635.28亿
总股本
16.23亿
成交额
2.87亿
换手率
0.45%
流通股本
16.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
信达生物将在美国临床肿瘤学会(ASCO)2024年大会公布多项临床数据
美通社 · 04-25 09:50
信达生物将在美国临床肿瘤学会(ASCO)2024年大会公布多项临床数据
信达生物现涨超6% 机构预计减肥药的上市数量将大幅增加
新浪港股 · 04-24 15:35
信达生物现涨超6% 机构预计减肥药的上市数量将大幅增加
港股异动 | 信达生物(01801)再涨超6% 减肥产品需求激增 公司产品玛仕度肽已递交减重适应症上市申请
智通财经 · 04-24 15:26
港股异动 | 信达生物(01801)再涨超6% 减肥产品需求激增 公司产品玛仕度肽已递交减重适应症上市申请
信达生物盘中异动 急速上涨5.12%报38.001港元
自选股智能写手 · 04-24 13:28
信达生物盘中异动 急速上涨5.12%报38.001港元
信达生物涨幅持续扩大逾7% 胆管癌治疗药物达伯坦在澳门获批上市
新浪港股 · 04-23
信达生物涨幅持续扩大逾7% 胆管癌治疗药物达伯坦在澳门获批上市
生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量
金吾财讯 · 04-23
生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量
港股异动 | 信达生物(01801)午后涨超5% 胆管癌治疗药物达伯坦在中国澳门获批上市
智通财经网 · 04-23
港股异动 | 信达生物(01801)午后涨超5% 胆管癌治疗药物达伯坦在中国澳门获批上市
信达生物盘中异动 大幅上涨5.01%报35.651港元
自选股智能写手 · 04-23
信达生物盘中异动 大幅上涨5.01%报35.651港元
信达生物4月19日获南向资金加仓141.05万股
自选股智能写手 · 04-22
信达生物4月19日获南向资金加仓141.05万股
降脂药赛道大变局:他汀药物时代正在逝去
华尔街见闻 · 04-17
降脂药赛道大变局:他汀药物时代正在逝去
信达生物04月16日主力资金流出173万元 连续3日减仓
自选股智能写手 · 04-16
信达生物04月16日主力资金流出173万元 连续3日减仓
【券商聚焦】招银国际料今年中国医药行业有望回归健康增长
金吾财讯 · 04-16
【券商聚焦】招银国际料今年中国医药行业有望回归健康增长
信达生物宣布任命Nageatte Ibrahim博士为肿瘤学首席医学官
美通社 · 04-16
信达生物宣布任命Nageatte Ibrahim博士为肿瘤学首席医学官
信达生物制药(苏州)有限公司药品申请临床试验默示许可获受理
金融界 · 04-15
信达生物制药(苏州)有限公司药品申请临床试验默示许可获受理
南向资金4月12日净买入信达生物100.76万股 连续3日增持
自选股智能写手 · 04-15
南向资金4月12日净买入信达生物100.76万股 连续3日增持
信达生物4月11日获南向资金加仓180.66万股
自选股智能写手 · 04-12
信达生物4月11日获南向资金加仓180.66万股
信达生物4月8日遭南向资金减持257.41万股
自选股智能写手 · 04-09
信达生物4月8日遭南向资金减持257.41万股
信达生物制药(苏州)有限公司药品纳入突破性治疗药物程序
金融界 · 04-09
信达生物制药(苏州)有限公司药品纳入突破性治疗药物程序
信达生物在美国癌症研究协会(AACR)2024年会公布多项创新管线的临床前数据
美通社 · 04-08
信达生物在美国癌症研究协会(AACR)2024年会公布多项创新管线的临床前数据
信达生物04月03日遭主力抛售1079万元 环比增加408.96%
自选股智能写手 · 04-03
信达生物04月03日遭主力抛售1079万元 环比增加408.96%
加载更多
公司概况
公司名称:
信达生物
所属市场:
SEHK
上市日期:
--
主营业务:
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
发行价格:
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":39.15,"timestamp":1714118900013,"preClose":38.55,"halted":0,"volume":7286643,"delay":0,"floatShares":1622682897,"shares":1622682897,"eps":-0.7103609,"marketStatus":"休市中","marketStatusCode":7,"change":0.6,"latestTime":"04-26 16:08:20","open":39.15,"high":39.95,"low":38.5,"amount":286534850,"amplitude":0.037613,"askPrice":39.15,"askSize":18500,"bidPrice":39.1,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-0.711362209470726,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714354200000},"adr":0,"listingDate":1540915200000,"adjPreClose":38.55,"openAndCloseTimeList":[[1714095000000,1714104000000],[1714107600000,1714118400000]],"volumeRatio":1.0205398329263589,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2430589417","title":"信达生物将在美国临床肿瘤学会(ASCO)2024年大会公布多项临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2430589417","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2430589417?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:50","pubTimestamp":1714009800,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年4月25日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司,今日宣布,将在 2024 年美国临床肿瘤学会年会上公布约20项最新临床研究数据,包括公司旗下一系列单抗、双抗及抗体偶联药物在研管线,及达伯舒、耐立克、他雷替尼等创新肿瘤药物。本届 ASCO 年会将于当地时间2024年5月31日-6月4日在美国芝加哥举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4396236_ZH96236_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429483717","title":"信达生物现涨超6% 机构预计减肥药的上市数量将大幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2429483717","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429483717?lang=zh_cn&edition=full","pubTime":"2024-04-24 15:35","pubTimestamp":1713944147,"startTime":"0","endTime":"0","summary":"信达生物(01801)尾盘上涨6.36%,现报38.45港元,成交额3.12亿港元。\n Global Data发布报告称,由于对减肥产品的需求激增,制药商正准备在未来五年内在美国推出约13种新的减肥疗法。该机构表示,预计减肥药的上市数量将大幅增加,2027年和2028年将达到每年四款的峰值。相比之下,2019年至2023年间仅推出了三款产品。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-24/doc-inasxkky8588367.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-24/doc-inasxkky8588367.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429488264","title":"港股异动 | 信达生物(01801)再涨超6% 减肥产品需求激增 公司产品玛仕度肽已递交减重适应症上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2429488264","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429488264?lang=zh_cn&edition=full","pubTime":"2024-04-24 15:26","pubTimestamp":1713943585,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物再涨超6%,截至发稿,涨6.22%,报38.4港元,成交额2.99亿港元。消息面上,Global Data发布报告称,由于对减肥产品的需求激增,制药商正准备在未来五年内在美国推出约13种新的减肥疗法。该机构表示,预计减肥药的上市数量将大幅增加,2027年和2028年将达到每年四款的峰值。中信建投指出,信达生物于2024年2月7日向CDE正式递交玛仕度肽的上市申请,适应症为超重伴有相关疾病或肥胖患者,申请剂量为2、4、6mg。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108336.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429713106","title":"信达生物盘中异动 急速上涨5.12%报38.001港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429713106","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429713106?lang=zh_cn&edition=full","pubTime":"2024-04-24 13:28","pubTimestamp":1713936488,"startTime":"0","endTime":"0","summary":"2024年04月24日下午盘13时28分,信达生物股票出现波动,股价急速上涨5.12%。截至发稿,该股报38.001港元/股,成交量421.995万股,换手率0.26%,振幅5.81%。信达生物股票所在的药品行业中,整体涨幅为0.24%。其相关个股中,精优药业、信达生物、泰凌医药涨幅较大,振幅较大的相关个股有联康生物科技集团、君圣泰医药-B、开拓药业-B,振幅分别为12.79%、10.45%、8.33%。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240424132809861e86f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240424132809861e86f6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429909153","title":"信达生物涨幅持续扩大逾7% 胆管癌治疗药物达伯坦在澳门获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2429909153","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429909153?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:08","pubTimestamp":1713852502,"startTime":"0","endTime":"0","summary":"信达生物(01801)午后涨幅持续扩大,上涨6.92%,现报36.30港元,成交额1.87亿港元。\n 4月22日,信达生物制药宣布,达伯坦(佩米替尼片)获得中国澳门药物监督管理局(ISAF)批准上市,用于曾接受过全身性治疗后疾病恶化、肿瘤具有FGFR2融合或重排的局部晚期或转移性胆管癌的成人患者。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuzea8098863.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuzea8098863.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429027158","title":"生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2429027158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429027158?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:53","pubTimestamp":1713851628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块午后发力走高,药明合联 涨8.59%,荣昌生物涨6.53%,信达生物涨6.48%,康希诺生物涨6.4%,维亚生物涨5.88%,和黄医药涨5.58%,康方生物涨5.41%。华鑫证券表示,2024年1季度行业增长受到同期基数影响较为明显,如零售药店、POCT等,展望2024年全年,1季度高增长方向具有代表性,其增长趋势有望延续,医药行业依然有结构性增量。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935593","is_publish_highlight":false,"gpt_icon":0},{"id":"2429130659","title":"港股异动 | 信达生物(01801)午后涨超5% 胆管癌治疗药物达伯坦在中国澳门获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2429130659","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429130659?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:30","pubTimestamp":1713850237,"startTime":"0","endTime":"0","summary":"信达生物(01801)午后涨超5%,截至发稿,涨5.15%,报35.7港元,成交额1.31亿港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240423/20240423133222_66684.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240423/20240423133222_66684.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107382.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429613022","title":"信达生物盘中异动 大幅上涨5.01%报35.651港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429613022","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429613022?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:21","pubTimestamp":1713849695,"startTime":"0","endTime":"0","summary":"2024年04月23日下午盘13时21分,信达生物股票出现异动,股价急速上涨5.01%。截至发稿,该股报35.651港元/股,成交量343.052万股,换手率0.21%,振幅4.71%。信达生物股票所在的药品行业中,整体涨幅为0.19%。其相关个股中,泰凌医药、信达生物、和黄医药涨幅较大,振幅较大的相关个股有泰凌医药、联康生物科技集团、开拓药业-B,振幅分别为17.39%、12.05%、10.78%。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313213579228241&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313213579228241&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429896133","title":"信达生物4月19日获南向资金加仓141.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429896133","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429896133?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:31","pubTimestamp":1713749475,"startTime":"0","endTime":"0","summary":"4月19日, 南向资金增持信达生物141.05万股。截止当日收盘,港股通共持有信达生物32763.72万股,占流通股20.18%。港股通增持金额前五个股分别为腾讯控股、中国移动、建设银行、中国银行、中广核电力。信达生物近5个交易日下跌11.11%,港股通累计增持42.82万股;近20个交易日下跌14.43%,港股通累计减持998.67万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422094225879ed292&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422094225879ed292&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428679335","title":"降脂药赛道大变局:他汀药物时代正在逝去","url":"https://stock-news.laohu8.com/highlight/detail?id=2428679335","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2428679335?lang=zh_cn&edition=full","pubTime":"2024-04-17 08:52","pubTimestamp":1713315162,"startTime":"0","endTime":"0","summary":"新型降脂药PCSK9抑制剂在安全性和有效性方面均超越了他汀类药物,不仅为患者提供了更多降脂治疗方案,也让高血脂这个逐渐萎缩的赛道重新有了新的增长点。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/33e888f2-648a-44e6-b4c4-d354df21ccc6.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/33e888f2-648a-44e6-b4c4-d354df21ccc6.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712914","is_publish_highlight":false,"gpt_icon":0},{"id":"2427812625","title":"信达生物04月16日主力资金流出173万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2427812625","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427812625?lang=zh_cn&edition=full","pubTime":"2024-04-16 16:15","pubTimestamp":1713255321,"startTime":"0","endTime":"0","summary":"04月16日, 信达生物股价跌3.21%,报收34.70元,成交金额2.03亿元,换手率0.36%,振幅6.00%,量比1.04。信达生物今日主力资金净流出173万元,连续3日净流出,上一交易日主力净流出157万元,今日环比增加10.19%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为72.73%,平均跌幅为1.43%。该股近5个交易日下跌8.41%,主力资金累计净流出1574万元;近20日主力资金累计净流出9939万元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161615468b299220&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161615468b299220&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427139158","title":"【券商聚焦】招银国际料今年中国医药行业有望回归健康增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2427139158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2427139158?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:56","pubTimestamp":1713250565,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示,年初至今,MSCI中国医疗指数下跌22.7%,跑输MSCI中国指数23.3%。展望2024年,随着行业监管常态化进行,新冠基数影响逐渐消退,中国医药行业有望回归健康增长。另外,行业监管仍呈现持续高压态势,预计院内刚需将在下半年出现需求复苏。该行认为,行业严格监管或将常态化,然而,诊疗秩序逐步正常,院内产品和服务的需求仍将保持健康。考虑到基数原因,该行预期行业或将于今年下半年加速增长。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935150","is_publish_highlight":false,"gpt_icon":0},{"id":"2427859583","title":"信达生物宣布任命Nageatte Ibrahim博士为肿瘤学首席医学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2427859583","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2427859583?lang=zh_cn&edition=full","pubTime":"2024-04-16 08:00","pubTimestamp":1713225600,"startTime":"0","endTime":"0","summary":"Nageatte Ibrahim博士拥有在Merck公司(默沙东)和GSK公司超过11年的肿瘤领域工业界药品开发管理和9年医疗及医学院校工作经验。加入信达生物前,Ibrahim博士在Merck公司担任肿瘤临床开发副总裁。信达生物创始人、董事长兼首席执行官俞德超博士表示:\"热忱欢迎Nageatte Ibrahim博士加入信达生物并担任肿瘤学首席医学官,Ibrahim博士在临床开发肿瘤领域拥有丰富的经验以及卓越的领导能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4387679_ZH87679_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427847047","title":"信达生物制药(苏州)有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2427847047","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427847047?lang=zh_cn&edition=full","pubTime":"2024-04-15 15:21","pubTimestamp":1713165702,"startTime":"0","endTime":"0","summary":"4月15日,据CDE官网消息,信达生物制药(苏州)有限公司联合申请药品“IBI133”,获得临床试验默示许可,受理号CXSL2400085。公示信息显示,药品“IBI133”适应症:不可切除的局部晚期或转移性实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415152143877e4ae6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415152143877e4ae6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427658092","title":"南向资金4月12日净买入信达生物100.76万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427658092","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427658092?lang=zh_cn&edition=full","pubTime":"2024-04-15 09:31","pubTimestamp":1713144674,"startTime":"0","endTime":"0","summary":"4月12日, 南向资金增持信达生物100.76万股,连续3日增持。截止当日收盘,港股通共持有信达生物32720.91万股,占流通股20.15%。信达生物近5个交易日上涨4.48%,港股通累计增持73.06万股;近20个交易日下跌7.89%,港股通累计减持223.73万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415094618877cfdcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415094618877cfdcd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426249475","title":"信达生物4月11日获南向资金加仓180.66万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426249475","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426249475?lang=zh_cn&edition=full","pubTime":"2024-04-12 09:31","pubTimestamp":1712885470,"startTime":"0","endTime":"0","summary":"4月11日, 南向资金增持信达生物180.66万股。截止当日收盘,港股通共持有信达生物32620.15万股,占流通股20.09%。信达生物近5个交易日上涨3.46%,港股通累计减持188.26万股;近20个交易日下跌6.50%,港股通累计减持415.04万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404120942228b13c97e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404120942228b13c97e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426904936","title":"信达生物4月8日遭南向资金减持257.41万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426904936","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426904936?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:31","pubTimestamp":1712626288,"startTime":"0","endTime":"0","summary":"4月8日,南向资金减持信达生物257.41万股。截止当日收盘,港股通共持有信达生物32390.43万股,占流通股19.95%。港股通减持金额前五个股分别为赛生药业、联想集团、瑞声科技、安踏体育、汇丰控股。信达生物近5个交易日下跌4.94%,港股通累计减持287.71万股;近20个交易日下跌5.68%,港股通累计减持754.05万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090946228756aa1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090946228756aa1b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426623977","title":"信达生物制药(苏州)有限公司药品纳入突破性治疗药物程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2426623977","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426623977?lang=zh_cn&edition=full","pubTime":"2024-04-09 08:04","pubTimestamp":1712621076,"startTime":"0","endTime":"0","summary":"4月9日,据CDE官网消息,信达生物制药(苏州)有限公司、信达生物制药(苏州)有限公司联合申请的药品“IBI310”,经审核,同意纳入突破性治疗药物程序,公示截止日期2024年4月9日。公示详细信息显示,“BDB-001注射液”药品类型为治疗用生物制品,拟定适应症(或功能主治):本品联合信迪利单抗用于可切除的高微卫星不稳定性(MSI-H)或错配修复基因缺陷型(dMMR)结肠癌的新辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090825558b006e38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090825558b006e38&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425603401","title":"信达生物在美国癌症研究协会(AACR)2024年会公布多项创新管线的临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2425603401","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2425603401?lang=zh_cn&edition=full","pubTime":"2024-04-08 08:40","pubTimestamp":1712536800,"startTime":"0","endTime":"0","summary":"美国罗克维尔和中国苏州2024年4月8日 /美通社/ -- 信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司,今日宣布在 2024 年美国癌症研究协会年会上公布多项最新临床前数据,包括公司旗下一系列双抗及抗体偶联药物肿瘤管线。IBI343针对Claudin 18.2阳性HER2阴性胃癌的临床三期试验正在筹备中。ISAC 靶向肿瘤组织并特异性激活肿瘤内天然免疫细胞,激活下游免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4381495_ZH81495_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424898579","title":"信达生物04月03日遭主力抛售1079万元 环比增加408.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424898579","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424898579?lang=zh_cn&edition=full","pubTime":"2024-04-03 16:15","pubTimestamp":1712132150,"startTime":"0","endTime":"0","summary":"04月03日, 信达生物股价跌4.11%,报收36.15元,成交金额2.34亿元,换手率0.40%,振幅3.98%,量比0.86。信达生物今日主力资金净流出1079万元,连续3日净流出,上一交易日主力净流出212万元,今日环比增加408.96%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为70.00%,平均跌幅为1.35%。该股近5个交易日下跌2.82%,主力资金累计净流出492万元;近20日主力资金累计净流出5809万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031616178aec864b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031616178aec864b&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.1611},{"period":"1month","weight":0.0026},{"period":"3month","weight":0.1559},{"period":"6month","weight":-0.1433},{"period":"1year","weight":-0.009},{"period":"ytd","weight":-0.0982}],"compareEarnings":[{"period":"1week","weight":0.088},{"period":"1month","weight":0.0768},{"period":"3month","weight":0.1065},{"period":"6month","weight":0.0145},{"period":"1year","weight":-0.1103},{"period":"ytd","weight":0.0354}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.026025},{"month":5,"riseRate":0.4,"avgChangeRate":0.023793},{"month":6,"riseRate":0.6,"avgChangeRate":0.132633},{"month":7,"riseRate":0.2,"avgChangeRate":-0.046248},{"month":8,"riseRate":0.8,"avgChangeRate":-0.016733},{"month":9,"riseRate":0.6,"avgChangeRate":0.024076},{"month":10,"riseRate":0.4,"avgChangeRate":0.043974},{"month":11,"riseRate":0.5,"avgChangeRate":0.068539},{"month":12,"riseRate":0.5,"avgChangeRate":0.07208}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}